Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Benjamin Lacas; Alexandra Carmel; C. Landais; Stuart J. Wong; Lisa Licitra; Jeffrey Tobias; Barbara Burtness; Maria Grazia Ghi; Ezra E.W. Cohen; Cai Grau; Gregory T. Wolf; Ricardo Hitt; Renzo Corvò; Volker Budach; Shaleen Kumar; Sarbani Ghosh Laskar; Jean‐Jacques Mazeron; Lai‐ping Zhong; W. Dobrowsky; Pirus Ghadjar; C. Fallai; Branko Zakotnik; Atul Sharma; René‐Jean Bensadoun; Maria Grazia Ruo Redda; S. Racadot; George Fountzilas; David M. Brizel; P Rovea; Athanassios Argiris; Zoltán Takácsi Nagy; Ju‐Whei Lee; Catherine Fortpied; Jonathan Harris; Jean Bourhis; Anne Aupérin; Pierre Blanchard; Jean‐Pierre Pignon; David J. Adelstein; M. Alfonsi; Y. Belkacemi; Voichita Bar‐Ad; J. Bernier; Åse Bratland; G. Calais; Brittany Campbell; Jimmy J. Caudell; Sylvie Chabaud; Emmanuel Chamorey; Devendra Chaukar; Kwang Nam Choi; Olivier Choussy; Laurence Collette; Judith Cruz; Carla Dani; Etienne Dauzier; Arlene A. Forastiere; P. Garaud; V. Grégoire; A. Hackshaw; E. Haddad; Bruce G. Haffty; Aaron R. Hansen; Stefanie Hayoz; Jean-Claude Horiot; Branislav Jeremić; Theodore Karrison; Johannes A. Langendijk; M. Lapeyre; Éric Lartigau; Traci Leong; Quynh‐Thu Le; Patricia Lee; Freddi Lewin; Aihua Lin; Alberto Lopes; Samir Mehta; James Moon; Elizabeth Moyal; Bob‐Valéry Occéan; P. Olmi; Roberto Orecchia; Brian O’Sullivan; Jens Overgaard; Claire Petit; Harvey Quon; Giuseppe Sanguineti; Tuvana Satar; John Simes; Christian Simon; Clément Sire; S. Staar; C. Stromberger; P. Strojan; Stéphane Temam; David Thomson; A. Timochenko; Valter Torri; Vassilikì Tseroni; Jan B. Vermorken

doi:10.1016/j.radonc.2021.01.013

January 27, 2021Radiotherapy and OncologyOpen Access

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

View Full Paper

Ask AI

Bookmark

Share

Key Points

To update the MACH-NC collaborative meta-analysis evaluating the clinical efficacy and benefit of adding chemotherapy to primary treatment in non-metastatic head and neck cancer.
Conducted an updated meta-analysis of individual patient data across 107 randomized controlled trials.
Included 19,805 patients diagnosed with non-metastatic head and neck cancer.
Evaluated the specific therapeutic effect of adding concomitant chemotherapy.
Confirmed a statistically significant survival benefit with the addition of concomitant chemotherapy.
Demonstrated the clinical superiority of concomitant chemotherapy compared to alternative treatment timing and regimens.

Implication

Meta-analysis reveals superior outcomes with concomitant chemotherapy in non-metastatic head and neck cancer, indicating clear clinical benefit.

Abstract

The update of MACH-NC confirms the benefit and superiority of the addition of concomitant CT for non-metastatic head and neck cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lacas et al. (2021) studied this question.

synapsesocial.com/papers/69dac4f478a3e0e288684510 https://doi.org/10.1016/j.radonc.2021.01.013

View Full Paper

Ask AI

Bookmark

Share

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Key Points

Implication

Abstract

Discussion

Cite This Study

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Radiotherapy and Oncology

Keep reading

More related papers

More from Radiotherapy and Oncology